Senseonics and Sequel Med Tech Collaborate on Groundbreaking Diabetes Management System

Senseonics and Sequel Med Tech have announced a collaborative effort to create the first automated insulin delivery (AID) system powered by a one-year continuous glucose monitor (CGM). This innovative partnership aims to revolutionize diabetes management for individuals with Type 1 diabetes.

Integration of Long-term CGM and Advanced Insulin Pump

The collaboration will combine Senseonics' Eversense 365 CGM with Sequel Med Tech's twiist insulin pump. The Eversense 365, a year-long integrated CGM implant, received FDA clearance in September for use in people aged 18 and older. This long-term CGM solution builds upon previous 90- and 180-day versions, offering extended monitoring capabilities.

Sequel's twiist insulin pump, developed in partnership with Dean Kamen's Deka Research & Development firm, incorporates dosing algorithms powered by Tidepool. The FDA cleared the twiist pump for use in Type 1 diabetes patients aged six and up last year.

Launch Timeline and Market Implications

The companies have set an ambitious timeline for the combined system, with a launch slated for the third quarter of this year. This rapid deployment highlights the urgency in addressing the needs of diabetes patients seeking more convenient and effective management solutions.

Tim Goodnow, President and CEO of Senseonics, emphasized the significance of this collaboration, stating, "People with diabetes who choose the convenience and ease of our one-year CGM sensor have been waiting for a compatible AID system to enhance their diabetes management." He added that the synergy between Eversense and twiist would provide users with an AID solution that "unlocks the full experience of our year-long CGM technology."

Expanding Compatibility and Market Reach

This announcement follows Sequel's recent news of the twiist pump's compatibility with Abbott's FreeStyle Libre 3 Plus CGM platform. By partnering with multiple CGM providers, Sequel is positioning its twiist pump as a versatile solution in the competitive diabetes management market.

The integration of these advanced technologies promises to simplify diabetes management, offering users a comprehensive solution that combines the benefits of long-term glucose monitoring with precise insulin delivery. As the diabetes care landscape continues to evolve, collaborations like this one between Senseonics and Sequel Med Tech are poised to drive innovation and improve patient outcomes.